{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:01:38Z","timestamp":1785405698891,"version":"3.56.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Gastric carcinosarcoma is most frequently diagnosed at an advanced stage when the tumor is generally large with invasion into other organs, lymph node metastasis, and distant metastasis. Standard chemotherapy has not been established, and surgery is the only curative treatment. Here, we present a case of postoperative recurrence of gastric carcinosarcoma under long-term tumor control with pazopanib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 77-year-old man was referred to our hospital because of nausea and vomiting. Computed tomography and upper gastrointestinal endoscopy revealed a type 1 tumor arising from the gastric antrum and extending into the duodenal bulb. He underwent distal gastrectomy (D2) with Roux-en-Y reconstruction. Histopathologically, the tumor had mixed adenocarcinoma and sarcoma components. According to the tumor\u2013node\u2013metastasis classification, the diagnosis was primary gastric carcinosarcoma pT1bN1M0 stage IB. Liver metastasis was detected 2 months after surgery; multiple lung metastases were detected 17 month after surgery. A genomic profiling test was performed using liver specimens as the patient became refractory to chemotherapy commonly used for gastric cancer, and the test revealed<jats:italic>FGFR2<\/jats:italic>amplification along with<jats:italic>TP53<\/jats:italic>R209*,<jats:italic>AKT3<\/jats:italic>N127D,<jats:italic>NOTCH1<\/jats:italic>A2036T, and<jats:italic>POLD1<\/jats:italic>M161I. The patient was treated with pazopanib (800\u00a0mg\/daily), and the tumor growth was controlled for 11 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We report a case of postoperative recurrence of gastric carcinosarcoma under long-term tumor control with pazopanib. This case suggested that pazopanib may be effective in treating gastric carcinosarcoma.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-022-02432-5","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T09:05:32Z","timestamp":1658999132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gastric carcinosarcoma with FGFR2 amplification under long-term control with pazopanib: a case report and literature review"],"prefix":"10.1186","volume":"22","author":[{"given":"Hirokatsu","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Yasufuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Saigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"2432_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.33160\/yam.2017.12.006","volume":"60","author":"H Kuroda","year":"2017","unstructured":"Kuroda H, Saito H, Kono Y, Murakami Y, Shishido Y, Matsunaga T, et al. Carcinosarcoma of stomach confined to the mucosa. Yonago Acta Med. 2017;60:246\u201350.","journal-title":"Yonago Acta Med"},{"key":"2432_CR2","first-page":"1262","volume":"23","author":"II Lazaridis","year":"2018","unstructured":"Lazaridis II, Lazaridis LD, Spartalis E, Frountzas M, Schizas D. Gastric carcinosarcoma: a rare clinical entity looking for an identity. J Buon. 2018;23:1262\u20135.","journal-title":"J Buon"},{"key":"2432_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00428-002-0725-7","volume":"442","author":"K Yamazaki","year":"2003","unstructured":"Yamazaki K. A gastric carcinosarcoma with neuroendocrine cell differentiation and undifferentiated spindle-shaped sarcoma component possibly progressing from the conventional tubular adenocarcinoma; an immunohistochemical and ultrastructural study. Virchows Arch. 2003;442:77\u201381.","journal-title":"Virchows Arch"},{"key":"2432_CR4","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/1097-0142(19900401)65:7<1601::AID-CNCR2820650725>3.0.CO;2-N","volume":"65","author":"SS Robey-Cafferty","year":"1990","unstructured":"Robey-Cafferty SS, Grignon DJ, Ro JY, Cleary KR, Ayala AG, Ordonez NG, et al. Sarcomatoid carcinoma of the stomach. A report of three cases with immunohistochemical and ultrastructural observations. Cancer. 1990;65:1601\u20136.","journal-title":"Cancer"},{"key":"2432_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijscr.2012.07.001","volume":"3","author":"F Selcukbiricik","year":"2012","unstructured":"Selcukbiricik F, Tural D, Senel ET, Dervisoglu S, Serdengecti S. Gastric carcinoma with osteoblastic differentiation. Int J Surg Case Rep. 2012;3:516\u20139.","journal-title":"Int J Surg Case Rep"},{"key":"2432_CR6","doi-asserted-by":"crossref","unstructured":"Omori H, Onuma H, Nio Y, Sato Y, Takubo K, Takeda H. A case report of gastric carcinosarcoma with rhabdomyosarcomatous differentiation. J Jpn Surg Assoc 2007;63. 2014;111;76\u201380:105\u201314.","DOI":"10.3919\/jjsa.68.76"},{"key":"2432_CR7","first-page":"105","volume":"111","author":"A Miyakawa","year":"2014","unstructured":"Miyakawa A, Ishibashi H, Takashina A, Ishigaki K, Iwai Y, Abe H, et al. A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy. Nihon Shokakibyo Gakkai Zasshi. 2014;111:105\u201314.","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"2432_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.critrevonc.2013.08.012","volume":"89","author":"G Ranieri","year":"2014","unstructured":"Ranieri G, Mamm\u00ec M, Donato Di Paola E, Russo E, Gallelli L, Citraro R, et al. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Crit Rev Oncol Hematol. 2014;89:322\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2432_CR9","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","volume":"21","author":"M Touat","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S, Andr\u00e9 F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21:2684\u201394.","journal-title":"Clin Cancer Res"},{"key":"2432_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22:259\u201367.","journal-title":"Clin Cancer Res"},{"key":"2432_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318\u201332.","journal-title":"Nat Rev Cancer"},{"key":"2432_CR12","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/1535-7163.MCT-14-0255","volume":"13","author":"ST Kim","year":"2014","unstructured":"Kim ST, Jang HL, Lee SJ, Lee J, Choi YL, Kim KM, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. 2014;13:2527\u201336.","journal-title":"Mol Cancer Ther"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02432-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T21:01:30Z","timestamp":1676235690000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02432-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2432"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02432-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was approved by the ethics committee of Gifu University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the patient\u2019s written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}